Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. in its US$82.5 million initial public offering

Client

Milestone Pharmaceuticals Inc.

Value

US$82.5 million

Service

Capital Markets

Date Closed

May 2019

Lead Office

Montréal


 

On May 13, 2019, Milestone Pharmaceuticals Inc. announced the closing of its previously announced initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.
Milestone Pharmaceuticals Inc., a Montreal-based company, is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications.

Osler, Hoskin & Harcourt LLP advised Milestone Pharmaceuticals Inc. with a team led by Nathalie Beauregard (Corporate) and consisting of Jeremy Brisset, Fancois Paradis, and Daniel Stysis (Corporate). 


Team
Jeremy Brisset

Jeremy Brisset

Associate, Corporate

François Paradis

François Paradis

Partner, Corporate

Daniel Stysis

Daniel Stysis

Associate, Corporate